General Overview of ASCO GI Alberto Zaniboni Oncologia Medica Fondazione Poliambulanza - Brescia

Transcription

1 General Overview of ASCO GI 2018 Alberto Zaniboni Oncologia Medica Fondazione Poliambulanza - Brescia

2 Le mie disclosures Research grants: Roche, Novartis, Pfizer, Astra Zeneca, Janssen, Boheringer Advisory boards / Speaker Bureau: Amgen, Merk Serono, Bayer, Servier, BMS, Lilly, Sanofi

3 ASCO GI 2018

4 Esophageal and GEJ Adenocarcinoma: Current Outcomes + Future Directions Presented By David Ilson at 2018 Gastrointestinal Cancers Symposium

5 Esophageal and GEJ Adenocarcinoma: Current Outcomes + Future Directions Presented By David Ilson at 2018 Gastrointestinal Cancers Symposium

6 FLOT4 Study Design Presented By Jaffer Ajani at 2018 Gastrointestinal Cancers Symposium

7 Since 2006: 5-Y OS nearly doubled compared with surgery alone Presented By Salah-Eddin Al-Batran at 2018 Gastrointestinal Cancers Symposium

8 Slide 15 Presented By Salah-Eddin Al-Batran at 2018 Gastrointestinal Cancers Symposium

9 ECF or any of its modifications should be abandoned Presented By Jaffer Ajani at 2018 Gastrointestinal Cancers Symposium

10 FLOT should be reserved for an occasional patient Presented By Jaffer Ajani at 2018 Gastrointestinal Cancers Symposium

11 RAINFALL: A randomized, double-blind, placebo-controlled phase 3 study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma. Presented By Charles Fuchs at 2018 Gastrointestinal Cancers Symposium

12 RAINFALL Trial Design: Presented By Charles Fuchs at 2018 Gastrointestinal Cancers Symposium

13 Intraperitoneal immunotherapy with the bispecific anti-epcam x anti-cd3 directed antibody catumaxomab for patients with peritoneal carcinomatosis from gastric cancer final results of a randomized phase II AIO trial Presented By Florian Lordick at 2018 Gastrointestinal Cancers Symposium

14 Catumaxomab (CATU) Presented By Florian Lordick at 2018 Gastrointestinal Cancers Symposium

15 ASCO GI 2018

16 Duration of Adjuvant Therapy for Colon Cancer: Is 3 Months Enough?<br />The U.S. Perspective Presented By Jeffrey Meyerhardt at 2018 Gastrointestinal Cancers Symposium

17 Duration of Adjuvant Therapy for Colon Cancer is 3 Months Enough?<br />The European Perspective Presented By Timothy Iveson at 2018 Gastrointestinal Cancers Symposium

18 6 months after ASCO: How are IDEA Results Being Interpreted/Incorporated Presented By Jeffrey Meyerhardt at 2018 Gastrointestinal Cancers Symposium

19 ARS 1: 34-year-old male with well differentiated, T3 colon cancer with 1 of 15 positive lymph nodes. What would you recommend for adjuvant therapy? Presented By Jeffrey Meyerhardt at 2018 Gastrointestinal Cancers Symposium

20 Colorectal Cancer With Peritoneal Metastasis: A Regional Disease Requiring Regional Therapy<br />CON Presented By Garrett Nash at 2018 Gastrointestinal Cancers Symposium

21 Role of (Neo) Adjuvant Chemotherapy for Rectal Cancer<br />The European approach Presented By Cornelis Van De Velde at 2018 Gastrointestinal Cancers Symposium

22 Nivolumab in Patients With DNA Mismatch <br />Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer: Long-Term Survival According to Prior Line of Treatment From <br />CheckMate-142 Presented By Michael Overman at 2018 Gastrointestinal Cancers Symposium

23 Nivolumab + Ipilimumab Combination in Patients <br />With DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer: <br />First Report of the Full Cohort From CheckMate-142 Presented By Thierry Andre at 2018 Gastrointestinal Cancers Symposium

24 Slide 1 Presented By Johanna Bendell at 2018 Gastrointestinal Cancers Symposium

25 Slide 1 Presented By Kohei Shitara at 2018 Gastrointestinal Cancers Symposium

26

27 ASCO GI 2018

28 Slide 1 Presented By Juan Valle at 2018 Gastrointestinal Cancers Symposium

29 Stereotactic Body Radiotherapy (SBRT); What Role Does Focal Radiotherapy Play for Hepatocellular Carcinoma Presented By Jinsil Seong at 2018 Gastrointestinal Cancers Symposium

30 Slide 1 Presented By Ann-Lii Cheng at 2018 Gastrointestinal Cancers Symposium

31 Conclusions<br />(2018 perspective of systemic tx for HCC) Presented By Ann-Lii Cheng at 2018 Gastrointestinal Cancers Symposium

32 Slide 2 Presented By Jordi Bruix at 2018 Gastrointestinal Cancers Symposium

33 Slide 1 Presented By Masatoshi Kudo at 2018 Gastrointestinal Cancers Symposium

34 KEYNOTE-224: Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib Presented By Andrew Zhu at 2018 Gastrointestinal Cancers Symposium

35 Cabozantinib versus placebo in patients with advanced hepatocellular carcinoma who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial Presented By Ghassan Abou-Alfa at 2018 Gastrointestinal Cancers Symposium

36 Slide 1 Presented By Ramesh Ramanathan at 2018 Gastrointestinal Cancers Symposium

37 ABSTRACT 204 Presented By Pascal Hammel at 2018 Gastrointestinal Cancers Symposium